Indonesia Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care) - Forecasts From 2023 To 2028

  • Published : Apr 2023
  • Report Code : KSI061615165
  • Pages : 80

The Indonesia CGM market is expected to grow at a CAGR of 16.93%, from an initial value of US$ 0.984 million in 2021 to US$2.941 million by 2028.

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

In Indonesia, diabetes is seen as a serious health issue and has raised concerns. To address the rising number of diabetics in Indonesia, diabetes professionals have developed suggestions for avoiding and controlling the disease. To avoid major side effects such as neuropathy, nephropathy, retinopathy, microvascular disease, and cardiovascular disease, diabetes control is essential. These treatments are only accessible because of diabetes education initiatives that encourage self-care. In Indonesia, healthcare practitioners provide diabetes education programs. A lack of skilled healthcare professionals (HCPs) to teach people with diabetes is caused by the limited availability of certified diabetic educators in Indonesia.

The market for continuous glucose monitoring systems in Indonesia has grown significantly as a result of the rising prevalence of diabetes and increased R&D. Diabetes cases are on the rise in the nation, which may be related to people's bad eating patterns, sedentary lives, and lack of exercise. The market does, however, confront certain obstacles to expansion, such as problems with government permission and regulation.

Increasing patients with Type-1 diabetes in Indonesia to surge growth.

Indonesia is the eighth most diabetic country in the world. The national government's insurance program mostly covers people's health costs in Indonesia. Medical necessities including consultations, hospital stays, insulin, and needles are covered by government insurance when obtained from specific clinics, hospitals, or approved pharmacies. Type-1 diabetes has been prevailing in the nation and hence the use of CGM to conquer this has been growing.

Increasing technological advancements to surge growth.

The market's expansion can also be attributed to the rising medical technology advancements, the expanding use of IT in healthcare, the surge in demand for mobile health (mhealth) applications, supported by the nation's growing internet user population, and the rising use of smart wearables by its citizens. In addition, it is anticipated that the nation's rising health expenditures would open up considerable prospects for market expansion in the years to come.

Market Key Developments

  • In February 2023, the Dexcom G6 CGM System has been introduced by Dexcom, Inc., a leader in real-time continuous glucose monitoring (CGM) for diabetics.
  • In May 2022, Abbott got FDA approval for the FreeStyle Libre 3 continuous glucose monitor.

Indonesia Continuous Glucose Monitoring (CGM) Market Scope:


Report Metric Details
Market Size Value in 2021 US$ 0.984 million
Market Size Value in 2028 US$2.941 million
Growth Rate CAGR of 16.93% from 2021 to 2028
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Million
Segments Covered Application and End-User Industry 
Companies Covered Dexcom, Inc., Abbott Laboratories, Medtronic plc, Sanofi, Roche Diabetes Care, Inc., Ypsomed AG, Insulet Corporation
Customization Scope Free report customization with purchase



  • By Application
    • Diabetes Patients
    • Critical Patients
  • By End-User Industry
    • Hospitals
    • Diagnostic Centers & Clinics
    • Home Care


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients


6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care


7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix


8.1. Dexcom, Inc.

8.2. Abbott Laboratories

8.3. Medtronic plc

8.4. Sanofi

8.5. Roche Diabetes Care, Inc.

8.6. Ypsomed AG

8.7. Insulet Corporation

Dexcom, Inc.

Abbott Laboratories

Medtronic plc


Roche Diabetes Care, Inc.

Ypsomed AG

Insulet Corporation

Related Reports

Report Name Published Month Get Sample PDF